著者

額田坦著

出版者

芙蓉書房

巻号頁・発行日

1977

著者

西浦進著

出版者

日本経済新聞出版社

巻号頁・発行日

2014

著者

保阪正康著

出版者

朝日新聞社

巻号頁・発行日

2006

著者

上法快男編

出版者

芙蓉書房

巻号頁・発行日

1976

著者

武藤章著

出版者

中央公論新社

巻号頁・発行日

2008

著者

日向 康吉

出版者

公益社団法人 日本農芸化学会

雑誌

化学と生物 (ISSN:0453073X)

巻号頁・発行日

vol.22, no.12, pp.833-840, 1984-12-25 (Released:2009-05-25)

参考文献数

14

被引用文献数

1 1

著者

永田 栄一郎

出版者

日本神経学会

雑誌

臨床神経学 (ISSN:0009918X)

巻号頁・発行日

vol.52, no.11, pp.1014-1017, 2012 (Released:2012-11-29)

参考文献数

7

---

The diagnosis of migraine can be difficult, even for headache specialists, because some patients do not necessarily fulfill the International Headache Society criteria for migraine. Hence, reliable disease markers of migraine are required for accurate migraine diagnosis. We performed "Omics" analysis such as transcriptomics, proteomics, and genomics utilizing the lymphoblast cell lines and serum obtained from migraineurs. We verified that αfodrin, which was among the identified 15 genes that were differentially expressed in lymphoblasts originating from patients with migraine, increased after cortical spreading depression in an animal model. We also investigated the alterations of protein expressions induced by migraine attacks using proteomics analysis. Notably, in two migraineurs, the level of apolipoprotein E protein expression during attacks was significantly higher than pre-attack levels. Recently, we have found a novel family lineage with migraine. They also exhibit severe myalgia with arms and legs. GC binding protein which binds to vitamin D was identified as the product of the causative gene in this family. Our omics approach will contribute to a better understanding of migraine pathophysiology.

著者

小林 稔治 橘川 千里

出版者

一般社団法人 映像情報メディア学会

雑誌

テレビジョン学会技術報告 (ISSN:03864227)

巻号頁・発行日

vol.19, no.27, pp.15-19, 1995-05-26 (Released:2017-10-13)

---

Picture MD has been finalized the specification, based on its MD DATA storage format. Picture MD enables the user to store color still images on a 64 mm diameter disc. This format covers such items as image size, resolution and compression method, thus enabling MD DATA discs to be compatible among a variety of future products, such as digital still picture cameras, devices which combine sound and still images for presentations, etc.

著者

重田 定明

出版者

The Japanese Society of Printing Science and Technology

雑誌

日本印刷学会誌 (ISSN:09143319)

巻号頁・発行日

vol.32, no.5, pp.284-289, 1995-09-30 (Released:2010-09-27)

参考文献数

6

---

In 1990, 5. 25 “mageneto-optical disk (MO) was released on the market, conforming to ISO standard. After that, 5.25 MO has been steadily growing up and doing a great deal as a file-server application for workstation so called auto-changer. On the other hand, right after 3.5” MO (230MB) following 128MB had been introduced, 3.5 “MR market has been rapidly becoming popular due to reasonable prices and inprovements of drive functions. The future status of 3.5” MO whose maket expantion is expected is mainly described including the technologies for higher recording density.

著者

真継日雲 著

出版者

庚申堂書店

巻号頁・発行日

1922

著者

聞きて文 吉澤弥生

出版者

吉澤弥生

巻号頁・発行日

2011

著者

大蔵省印刷局 [編]

出版者

日本マイクロ写真

巻号頁・発行日

vol.1936年09月01日, 1936-09-01

著者

大蔵省印刷局 [編]

出版者

日本マイクロ写真

巻号頁・発行日

vol.1935年10月24日, 1935-10-24

著者

山辺 拓也 土谷 順彦

出版者

医学書院

巻号頁・発行日

pp.500-501, 2018-04-15

---

病態 放射線性膀胱炎は骨盤内の放射線治療に起因する出血性膀胱炎であり,骨盤内への放射線照射後6カ月〜10年で発症するとされている1).放射線治療の合併症のなかでも治療困難なものの1つであり,ひとたび発症してしまうと血尿,膀胱刺激症状が認められ,重症例では血尿のコントロールが困難となり,尿路変更術が必要になったり,時には致命的になったりすることさえある2).重篤な放射線性膀胱炎をきたした放射線治療の原疾患としては子宮頸癌が最も多く,ほかに直腸癌,膀胱癌,前立腺癌などが原因となり得る.照射線量が50Gy以下では発症頻度は約3%に過ぎないが,80Gyを越すと12%に達するとの報告や,90Gy以上ではGrade 2,3(表1)3)の放射線性膀胱炎の発症頻度が急増するといった報告が認められ,照射線量が増えるに従って発症の危険性が高くなることがわかっている4). 放射線障害の本態は血管内皮細胞による進行性の閉塞性動脈内膜炎であり,組織が傍血管性,低細胞性,低酸素状態になることとされている.病理学的には粘膜浮腫,血管拡張,閉塞性動脈内膜炎,平滑筋の線維化が認められる.通常の創傷治癒に必要な線維芽細胞が機能しないため,長期的には膀胱の線維化をきたす1).

著者

中央盲人福祉協会 編

出版者

中央盲人福祉協会

巻号頁・発行日

vol.昭和16年版, 1941

著者

呉服 栄太

出版者

湘南工科大学

巻号頁・発行日

2015-03-21

---

2014

著者

Yuki Miyamoto Hiroyuki Ohbe Miho Ishimaru Hiroki Matsui Kiyohide Fushimi Hideo Yasunaga

出版者

The Japanese Society of Internal Medicine

雑誌

Internal Medicine (ISSN:09182918)

巻号頁・発行日

vol.59, no.15, pp.1789-1794, 2020-08-01 (Released:2020-08-01)

参考文献数

13

被引用文献数

5

---

Objective Carbazochrome sodium sulfonate (CSS) has been routinely used to treat bleeding; however, no study has examined the effect of CSS for gastrointestinal bleeding. Therefore, we aimed to investigate the effect of CSS for colonic diverticular bleeding. Methods We performed a nationwide observational study using the Japanese Diagnosis Procedure Combination inpatient database. We identified patients who were admitted for diverticular bleeding from July 2010 to March 2018. Patients who received CSS on the day of admission were defined as the CSS group, and those not receiving CSS were defined as the control group. The primary outcome was in-hospital mortality. Secondary outcomes were length of stay, total costs, and blood transfusion within 7 days of admission. Propensity score matching analyses were performed to compare outcomes between the two groups. Results A total of 59,965 patients met our eligibility criteria. Of these, 14,437 (24%) patients received CSS on the day of admission. One-to-one propensity score matching created 14,379 matched pairs. There was no significant difference in the in-hospital mortality between the CSS and control groups (0.6% vs. 0.5%, respectively; odds ratio: 0.96; 95% confidence interval: 0.72-1.29). The length of stay was longer in the CSS group than in the control group (11.4 vs. 11.0 days, respectively; difference: 0.44; 95% confidence interval: 0.14-0.73). There were no significant differences in the total costs or the proportion of patients receiving blood transfusion between the groups. Conclusions CSS may not reduce in-hospital mortality, length of stay, total costs, or the need for blood transfusion in patients with colonic diverticular bleeding.

著者

Yoko Kado Masayuki Tsujimoto Shin-ichi Fuchida Akira Okano Mayumi Hatsuse Satoshi Murakami Hikofumi Sugii Kumi Ueda Yuki Toda Tetsuya Minegaki Kohshi Nishiguchi Yuichi Muraki Chihiro Shimazaki Eishi Ashihara

出版者

The Pharmaceutical Society of Japan

雑誌

Biological and Pharmaceutical Bulletin (ISSN:09186158)

巻号頁・発行日

vol.43, no.8, pp.1253-1258, 2020-08-01 (Released:2020-08-01)

参考文献数

19

被引用文献数

1

---

Long-term combination treatment with lenalidomide and low-dose dexamethasone is important to achieve a curative effect in patients with multiple myeloma (MM). In this study, the plasma concentration of lenalidomide was measured at 3 h after oral administration, when the drug is in the elimination phase and can be easily measured in outpatients, to identify factors that may lead to the discontinuation of this combination therapy. Patients were assigned to continuation or discontinuation of therapy groups, and the baseline characteristics of patients, lenalidomide concentration, and concentration/dose (C/D) ratios reflecting oral clearance were compared between the two groups. The efficacy and severity of adverse events were also compared. The results showed that patients who discontinued or modified treatment had low plasma concentrations of lenalidomide and C/D ratios, indicating high oral clearance of lenalidomide. The estimated creatinine clearance rate was negatively correlated with the C/D ratio. The plasma concentrations of lenalidomide were independent from kidney function and differed significantly among patients. Taken together, the results indicate that low plasma concentrations of lenalidomide and low C/D ratios may lead to discontinuation of combination therapy in patients with MM. This suggests that early measurement of lenalidomide plasma continuation would help to prevent discontinuation of therapy or a delay in modifying the dose of lenalidomide.

著者

Mayako Uchida Yuki Yamaguchi Syuhei Hosomi Hiroaki Ikesue Yasuhiro Mori Nami Maegawa Aoi Takano Yuki Sato Keiko Hosohata Nobuyuki Muroi Keisuke Tomii Tohru Hashida Tsutomu Nakamura

出版者

The Pharmaceutical Society of Japan

雑誌

Biological and Pharmaceutical Bulletin (ISSN:09186158)

巻号頁・発行日

vol.43, no.8, pp.1235-1240, 2020-08-01 (Released:2020-08-01)

参考文献数

42

被引用文献数

3

---

We retrospectively obtained data of patient background and pretreatment characteristics from medical records and identified the predictive factors of febrile neutropenia (FN) in patients with non-small cell lung cancer (NSCLC) treated with docetaxel alone or in combination with the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab. Patients were eligible for inclusion in the study if they were 20 years or older, diagnosed with NSCLC, and received docetaxel monotherapy alone or in combination with bevacizumab at the Department of Respiratory Medicine, Kobe City Medical Center General Hospital, between July 1, 2011, and March 31, 2018. Eighty-one patients with recurrent or advanced NSCLC were included. Multivariate stepwise logistic regression analysis with backward selection revealed that lower baseline Eastern Cooperative Oncology Group performance status (ECOG-PS) scores of 1 and 2 (odds ratio (OR), 5.098; 95% confidence interval (CI), 1.045–24.879, p = 0.021) and baseline platelet count below 18.8 × 104/µL (OR, 3.861; 95% CI, 1.211–12.311, p = 0.022) were significant factors influencing the FN occurrence rate. Our results demonstrated that ECOG-PS 1–2 and lower baseline platelet count were significant risk factors of FN in patients with NSCLC receiving docetaxel-based chemotherapy. Moreover, the combination of anti-VEGF antibodies and docetaxel might be associated with increased FN frequency. Despite the limitations of this study including its retrospective design, single-center site, and small sample size, baseline ECOG-PS score and platelet count may be regarded as important indices to identify patients for prophylactic granulocyte-colony stimulating factor (G-CSF) treatment before docetaxel-based chemotherapy.

著者

池上 知子 川西 千弘

出版者

公益社団法人 日本心理学会

雑誌

日本心理学会大会発表論文集 日本心理学会第70回大会 (ISSN:24337609)

巻号頁・発行日

pp.2EV044, 2006-11-03 (Released:2018-07-03)